Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 4
2(50.0%)
4Total
Phase 2(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04962126Phase 2Active Not Recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Role: collaborator

NCT06279260Recruiting

National Robotics-Assisted Radical Prostatectomy Database

Role: collaborator

NCT01568307Phase 4Completed

Major Depressive Disorder - Understanding The Link Between The Brain And The Heart

Role: collaborator

NCT01567124Phase 4Withdrawn

Alleviating the Metabolic Side Effects of Antipsychotic Medications

Role: collaborator

NCT00784667Phase 2Unknown

Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib

Role: collaborator

All 5 trials loaded